Jeandel C, Lapicque F, Netter P, Bannwarth B, Monot C, Gillet P, Payan E, Guillaume M, Cuny G
Département de Pharmacologie Clinique, URA CNRS 1288, Nancy, France.
Eur J Clin Pharmacol. 1992;43(3):295-7. doi: 10.1007/BF02333026.
Sodium fluoride (NaF) is used in the treatment of axial osteoporosis and so is mostly given to old patients. Since its pharmacokinetics has not been studied in the elderly, the pharmacokinetics of an enteric-coated tablet containing 50 mg NaF has been investigated in 15 aged inpatients (aged 65 to 75 y) and 12 young healthy volunteers (aged 21 to 26 y). The serum AUC of fluoride was 1.7-time higher in older than in younger subjects. There was a strong inverse correlation between the AUC and either body surface area (BSA) or glomerular filtration rate (GFR), both of which were very much lower in the elderly. This concluded that if efficacy or safety are related to the bioavailability of fluoride, it may be valuable to adjust the dosage of fluoride accordingly to the GFR and BSA.
氟化钠（NaF）用于治疗轴向骨质疏松症，因此主要用于老年患者。由于尚未在老年人中研究其药代动力学，因此已在15名老年住院患者（65至75岁）和12名年轻健康志愿者（21至26岁）中研究了含50mg NaF的肠溶衣片的药代动力学。老年人中氟化物的血清AUC比年轻人高1.7倍。AUC与体表面积（BSA）或肾小球滤过率（GFR）之间存在很强的负相关，而老年人的这两者均低得多。由此得出结论，如果疗效或安全性与氟化物的生物利用度有关，根据GFR和BSA相应调整氟化物的剂量可能是有价值的。
